Biological sex linked to protein changes in lung adenocarcinoma and other cancers, Sanford Burnham Prebys study finds

Ris-Rez improves overall survival in SCLC, phase III trial finds

ARTEMIS-008, a phase III trial evaluating Ris-Rez (risvutatug rezetecan) in patients with advanced or relapsed small-cell lung cancer, met its primary endpoint of overall survival.

July 17, 2026

Vol.52 No.28

News Analysis

A chronotherapy study in Nature Medicine showed dramatic results. Then it was retracted.
The phase III trial claimed a staggering boost to OS and PFS when immunochemotherapy was given before 3 p.m.

On Feb. 2, Nature Medicine published the results of a large, randomized, prospective clinical trial in the nascent and some say, fringe, field of chrono-oncology—the study of how natural biological rhythms might impact cancer outcomes.

Despite overall decline in secondary cancer diagnoses, female lung cancer survivors saw 60% increase from the 1970s to the 2010s, VCU Massey analysis finds

As people continue to live longer and the survival rate of cancer diagnoses increases, researchers from VCU Massey Comprehensive Cancer Center decided to lead a multi-decade analysis studying the rates of subsequent primary cancers, which are new cancers unrelated to the original diagnosis.

July 02, 2026

Vol.52 No.26

Clinical Roundup

Alliance launches study of immunotherapy to prevent lung cancer recurrence

The Alliance for Clinical Trials in Oncology has launched a new national study to see if an immune-boosting drug can help keep early-stage lung cancer from coming back after surgery.

July 02, 2026

Vol.52 No.26

Clinical Roundup

USC comparison study of leading targeted therapies for ALK+ lung cancer could lead to better treatment decisions

A head-to-head comparison of five leading treatments for anaplastic lymphoma kinase-positive non-small cell lung cancer could help oncologists fine-tune first-line TKI selection beyond what’s been seen in clinical trials alone, according to a study conducted by a team of researchers from the Keck School of Medicine of USC, the USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences and the USC Shaeffer Center for Health Policy & Economics have conducted.

May 22, 2026

Vol.52 No.20

Clinical Roundup

Despite breakthroughs, many go without treatment for metastatic lung cancer, MUSC study finds

About half of people diagnosed with metastatic non-small-cell lung cancer never receive treatment, despite advances in options over recent decades that have created meaningful improvements in lifespan and quality of life for many patients.

May 15, 2026

Vol.52 No.19

Biological sex linked to protein changes in lung adenocarcinoma and other cancers, Sanford Burnham Prebys study finds

YOU MAY BE INTERESTED IN

Ris-Rez improves overall survival in SCLC, phase III trial finds

A chronotherapy study in Nature Medicine showed dramatic results. Then it was retracted.
The phase III trial claimed a staggering boost to OS and PFS when immunochemotherapy was given before 3 p.m.

Despite overall decline in secondary cancer diagnoses, female lung cancer survivors saw 60% increase from the 1970s to the 2010s, VCU Massey analysis finds

Alliance launches study of immunotherapy to prevent lung cancer recurrence

USC comparison study of leading targeted therapies for ALK+ lung cancer could lead to better treatment decisions

Despite breakthroughs, many go without treatment for metastatic lung cancer, MUSC study finds

Renew today!

Subscriber content

Never miss an issue!

Login

Biological sex linked to protein changes in lung adenocarcinoma and other cancers, Sanford Burnham Prebys study finds

YOU MAY BE INTERESTED IN

Ris-Rez improves overall survival in SCLC, phase III trial finds

A chronotherapy study in Nature Medicine showed dramatic results. Then it was retracted.The phase III trial claimed a staggering boost to OS and PFS when immunochemotherapy was given before 3 p.m.

Despite overall decline in secondary cancer diagnoses, female lung cancer survivors saw 60% increase from the 1970s to the 2010s, VCU Massey analysis finds

Alliance launches study of immunotherapy to prevent lung cancer recurrence

USC comparison study of leading targeted therapies for ALK+ lung cancer could lead to better treatment decisions

Despite breakthroughs, many go without treatment for metastatic lung cancer, MUSC study finds

Never miss an issue!

Login

A chronotherapy study in Nature Medicine showed dramatic results. Then it was retracted.
The phase III trial claimed a staggering boost to OS and PFS when immunochemotherapy was given before 3 p.m.